Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Confirmatory trial of non-amputative digit preservation surgery for subungual melanoma: Japan Clinical Oncology Group study (JCOG1602, J-NAIL study protocol).
Tanaka K, Nakamura Y, Mizutani T, Shibata T, Tsutsumida A, Fukuda H, Matsushita S, Aoki M, Namikawa K, Ohe S, Fukushima S, Yamazaki N; Dermatologic Oncology Group of the Japan Clinical Oncology Group. Tanaka K, et al. Among authors: tsutsumida a. BMC Cancer. 2019 Oct 25;19(1):1002. doi: 10.1186/s12885-019-6248-2. BMC Cancer. 2019. PMID: 31653251 Free PMC article. Clinical Trial.
A double-blind, placebo-controlled study of the safety and efficacy of vitamin K1 ointment for the treatment of patients with cetuximab-induced acneiform eruption.
Hashimoto H, Iwasa S, Yanai T, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y, Namikawa K, Tsutsumida A, Yamazaki N, Yamamoto H. Hashimoto H, et al. Among authors: tsutsumida a. Jpn J Clin Oncol. 2013 Jan;43(1):92-4. doi: 10.1093/jjco/hys183. Epub 2012 Nov 6. Jpn J Clin Oncol. 2013. PMID: 23136238 Clinical Trial.
BRAF V600 mutations and pathological features in Japanese melanoma patients.
Yamazaki N, Tanaka R, Tsutsumida A, Namikawa K, Eguchi H, Omata W, Oashi K, Ogawa T, Hayashi A, Nakamura N, Tsuta K. Yamazaki N, et al. Among authors: tsutsumida a. Melanoma Res. 2015 Feb;25(1):9-14. doi: 10.1097/CMR.0000000000000091. Melanoma Res. 2015. PMID: 25051202 Free PMC article.
Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.
Yamazaki N, Uhara H, Fukushima S, Uchi H, Shibagaki N, Kiyohara Y, Tsutsumida A, Namikawa K, Okuyama R, Otsuka Y, Tokudome T. Yamazaki N, et al. Among authors: tsutsumida a. Cancer Chemother Pharmacol. 2015 Nov;76(5):969-75. doi: 10.1007/s00280-015-2870-0. Epub 2015 Sep 25. Cancer Chemother Pharmacol. 2015. PMID: 26407818 Free PMC article. Clinical Trial.
Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.
Yamazaki N, Kiyohara Y, Uhara H, Fukushima S, Uchi H, Shibagaki N, Tsutsumida A, Yoshikawa S, Okuyama R, Ito Y, Tokudome T. Yamazaki N, et al. Among authors: tsutsumida a. Cancer Chemother Pharmacol. 2015 Nov;76(5):997-1004. doi: 10.1007/s00280-015-2873-x. Epub 2015 Sep 26. Cancer Chemother Pharmacol. 2015. PMID: 26410424 Free PMC article. Clinical Trial.
58 results